Please use this identifier to cite or link to this item:
Type: Artigo de periódico
Title: Cost Analysis Of Pharmaceutical Care Provided To Hiv-infected Patients: An Ambispective Controlled Study.
Author: Carnevale, Renata Cavalcanti
de Godoi Rezende Costa Molino, Caroline
Visacri, Marília Berlofa
Mazzola, Priscila Gava
Moriel, Patricia
Abstract: Studies have shown that pharmaceutical care can result in favorable clinical outcomes in human immunodeficiency virus (HIV)-infected patients, however, few studies have assessed the economic impact. The objective of this study was to evaluate the clinical and economic impact of pharmaceutical care of HIV-infected patients. A controlled ambispective study was conducted in Brazil from January 2009 to June 2012. Patients were allocated to either intervention or control group. The control group was followed according to standard care while the intervention group was also followed by a pharmacist at each physician appointment for one year. Effectiveness outcomes included CD4+ count, viral load, absence of co-infections and optimal immune response, and economic outcomes included expenses of physician and pharmaceutical appointments, laboratory tests, procedures, and hospitalizations, at six months and one year. Intervention and control groups included 51 patients each. We observed significant decreases in total pharmacotherapy problems during the study. At six months, the intervention group contained higher percentages of patients without co-infections and of patients with CD4+ >500 cells/mm(3). None of the differences between intervention and control group considering clinical outcomes and costs were statistically significant. However, at one year, the intervention group showed higher percentage of better clinical outcomes and generated lower spending (not to procedures). An additional health care system daily investment of US$1.45, 1.09, 2.13, 4.35, 1.09, and 0.87 would be required for each additional outcome of viral load <50 copies/ml, absence of co-infection, CD4+ >200, 350, and 500 cells/mm(3), and optimal immune response, respectively. This work demonstrated that pharmaceutical care of HIV-infected patients, for a one-year period, was able to decrease the number of pharmacotherapy problems. However, the clinical outcomes and the costs did not have statistical difference but showed higher percentage of better clinical outcomes and lower costs for some items.
Subject: Adult
Cost-benefit Analysis
Hiv Infections
Health Care Costs
Middle Aged
Pharmaceutical Services
Prospective Studies
Retrospective Studies
Treatment Outcome
Citation: Daru : Journal Of Faculty Of Pharmacy, Tehran University Of Medical Sciences. v. 23, p. 13, 2015.
Rights: aberto
Identifier DOI: 10.1186/s40199-014-0074-5
Date Issue: 2015
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
File SizeFormat 
pmed_25889580.pdf671.33 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.